WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H574676
CAS#: 142057-80-5 (S-isomer)
Description: (-)-Donepezil is an isomer of Donepezil -- a nootropic acting as an inhibitor of acetylcholinesterase.
Hodoodo Cat#: H574676
Name: (-)-Donepezil
CAS#: 142057-80-5 (S-isomer)
Chemical Formula: C24H29NO3
Exact Mass: 379.21
Molecular Weight: 379.500
Elemental Analysis: C, 75.96; H, 7.70; N, 3.69; O, 12.65
Related CAS #: 120014-06-4 (free base) 120011-70-3 (HCl) 142698-19-9 (R-isomer) 142057-80-5 (S-isomer)
Synonym: (-)-Donepezil
IUPAC/Chemical Name: (S)-2,3-Dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-Inden-1-one
InChi Key: ADEBPBSSDYVVLD-FQEVSTJZSA-N
InChi Code: InChI=1S/C24H29NO3/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18/h3-7,14-15,17,20H,8-13,16H2,1-2H3/t20-/m0/s1
SMILES Code: O=C1[C@@H](CC2CCN(CC3=CC=CC=C3)CC2)CC4=C1C=C(OC)C(OC)=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 379.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Zhang N, Gordon ML. Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients. Clin Interv Aging. 2018 Oct 11;13:1963-1970. doi: 10.2147/CIA.S159920. PMID: 30349215; PMCID: PMC6187917.
2: Guo J, Wang Z, Liu R, Huang Y, Zhang N, Zhang R. Memantine, Donepezil, or Combination Therapy-What is the best therapy for Alzheimer's Disease? A Network Meta-Analysis. Brain Behav. 2020 Nov;10(11):e01831. doi: 10.1002/brb3.1831. Epub 2020 Sep 10. PMID: 32914577; PMCID: PMC7667299.
3: Govind N. Donepezil for dementia due to Alzheimer's disease. Br J Community Nurs. 2020 Mar 2;25(3):148-149. doi: 10.12968/bjcn.2020.25.3.148. PMID: 32160022.
4: Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019 Jul;140(3):291-294. doi: 10.1016/j.jphs.2019.05.009. Epub 2019 Jul 19. PMID: 31377017.
5: Zhang X, Lian S, Zhang Y, Zhao Q. Efficacy and safety of donepezil for mild cognitive impairment: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2022 Feb;213:107134. doi: 10.1016/j.clineuro.2022.107134. Epub 2022 Jan 19. PMID: 35078087.
6: Adelman M, Louis L. A Novel Formulation: Donepezil Patch. Sr Care Pharm. 2023 Jul 1;38(7):300-304. doi: 10.4140/TCP.n.2023.300. PMID: 37381137.
7: Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study. Cogn Behav Neurol. 2021 Dec 2;34(4):288-294. doi: 10.1097/WNN.0000000000000285. PMID: 34851866.
8: Barfejani AH, Jafarvand M, Seyedsaadat SM, Rasekhi RT. Donepezil in the treatment of ischemic stroke: Review and future perspective. Life Sci. 2020 Dec 15;263:118575. doi: 10.1016/j.lfs.2020.118575. Epub 2020 Oct 12. PMID: 33058916.
9: Mezeiova E, Chalupova K, Nepovimova E, Gorecki L, Prchal L, Malinak D, Kuca K, Soukup O, Korabecny J. Donepezil Derivatives Targeting Amyloid-β Cascade in Alzheimer's Disease. Curr Alzheimer Res. 2019;16(9):772-800. doi: 10.2174/1567205016666190228122956. PMID: 30819078.
10: Zhao ZQ, Chen BZ, Zhang XP, Zheng H, Guo XD. An Update on the Routes for the Delivery of Donepezil. Mol Pharm. 2021 Jul 5;18(7):2482-2494. doi: 10.1021/acs.molpharmaceut.1c00290. Epub 2021 Jun 8. PMID: 34100291.
11: Saeedi M, Mehranfar F. Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. Recent Pat Biotechnol. 2022;16(2):102-121. doi: 10.2174/1872208316666220302115901. PMID: 35236274.
12: Takada-Takatori Y. [Donepezil Reduces Amyloid Precursor Protein Endocytosis by Resulting from Increase in the Expression of Sorting Nexin Protein 33]. Yakugaku Zasshi. 2021;141(6):851-856. Japanese. doi: 10.1248/yakushi.20-00251-6. PMID: 34078793.
13: Rong X, Jiang L, Qu M, Hassan SSU, Liu Z. Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review. Curr Pharm Des. 2021;27(3):332-344. doi: 10.2174/1381612826666201023144836. PMID: 33100197.
14: Brewster JT 2nd, Dell'Acqua S, Thach DQ, Sessler JL. Classics in Chemical Neuroscience: Donepezil. ACS Chem Neurosci. 2019 Jan 16;10(1):155-167. doi: 10.1021/acschemneuro.8b00517. Epub 2018 Nov 8. PMID: 30372021.
15: Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. PMID: 33035532.
16: Fang X, Zhang J, Zhao J, Wang L. Effect of Resveratrol Combined with Donepezil Hydrochloride on Inflammatory Factor Level and Cognitive Function Level of Patients with Alzheimer's Disease. J Healthc Eng. 2022 Mar 25;2022:9148650. doi: 10.1155/2022/9148650. Retraction in: J Healthc Eng. 2023 Jan 25;2023:9834320. PMID: 35368930; PMCID: PMC8975642.
17: Rajput A, Butani S. Donepezil HCl Liposomes: Development, Characterization, Cytotoxicity, and Pharmacokinetic Study. AAPS PharmSciTech. 2022 Feb 11;23(2):74. doi: 10.1208/s12249-022-02209-9. PMID: 35149912.
18: Kho J, Ioannou A, Mandal AKJ, Missouris CG. Donepezil induces ventricular arrhythmias by delayed repolarisation. Naunyn Schmiedebergs Arch Pharmacol. 2021 Mar;394(3):559-560. doi: 10.1007/s00210-020-02028-4. Epub 2020 Nov 24. PMID: 33230575.
19: A donepezil patch (Adlarity) for Alzheimer's disease. Med Lett Drugs Ther. 2022 Aug 8;64(1656):e128-e129. PMID: 35921079.
20: Gao BL, Che NN, Li X, Ren CF. Neuroprotective effects of donepezil against Aβ25-35-induced neurotoxicity. Eur J Med Res. 2022 Oct 28;27(1):219. doi: 10.1186/s40001-022-00862-1. PMID: 36307893; PMCID: PMC9617393.
